Structural disease modification in axial spondyloarthritis

IF 4.5 2区医学 Q1 RHEUMATOLOGY

Best Practice & Research in Clinical Rheumatology Pub Date : 2023-09-01 DOI:10.1016/j.berh.2023.101898

Brona Dinneen , Finbar O’Shea , Lianne Gensler

{"title":"Structural disease modification in axial spondyloarthritis","authors":"Brona Dinneen , Finbar O’Shea , Lianne Gensler","doi":"10.1016/j.berh.2023.101898","DOIUrl":null,"url":null,"abstract":"<div>“Disease modification” in axial spondyloarthritis (axSpA) seeks to not only alleviate clinical symptoms but also alter the disease’s natural course by impeding new bone formation. Recent years have witnessed the effectiveness of treatments, including biologics and nonsteroidal anti-inflammatory drugs, in managing axSpA symptoms. Emerging evidence points toward their potential impact on slowing structural disease progression. This comprehensive review centers on the pivotal role of inhibiting new bone formation in axSpA disease modification. It delves into the significance of imaging techniques for assessing disease progression and explores the disease-modifying properties of available axSpA treatments, encompassing NSAIDs, TNF inhibitors, IL-17 inhibitors, and JAK inhibitors. This article offers valuable insights into the evolving landscape of disease modification strategies in axial spondyloarthritis, highlighting the multifaceted approaches used to attain these objectives.</div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"37 3","pages":"Article 101898"},"PeriodicalIF":4.5000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research in Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521694223000840","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

“Disease modification” in axial spondyloarthritis (axSpA) seeks to not only alleviate clinical symptoms but also alter the disease’s natural course by impeding new bone formation. Recent years have witnessed the effectiveness of treatments, including biologics and nonsteroidal anti-inflammatory drugs, in managing axSpA symptoms. Emerging evidence points toward their potential impact on slowing structural disease progression. This comprehensive review centers on the pivotal role of inhibiting new bone formation in axSpA disease modification. It delves into the significance of imaging techniques for assessing disease progression and explores the disease-modifying properties of available axSpA treatments, encompassing NSAIDs, TNF inhibitors, IL-17 inhibitors, and JAK inhibitors. This article offers valuable insights into the evolving landscape of disease modification strategies in axial spondyloarthritis, highlighting the multifaceted approaches used to attain these objectives.

查看原文本刊更多论文

轴性脊柱炎的结构性疾病改变。

轴性脊柱炎(axSpA)的“疾病改造”不仅寻求减轻临床症状，而且通过阻碍新骨形成来改变疾病的自然过程。近年来，包括生物制剂和非甾体抗炎药在内的治疗方法在治疗axSpA症状方面取得了成效。新出现的证据指出它们对减缓结构性疾病进展的潜在影响。本文综述了抑制新骨形成在axSpA疾病修饰中的关键作用。它深入探讨了成像技术对评估疾病进展的重要性，并探讨了可用的axSpA治疗方法的疾病改善特性，包括非甾体抗炎药、TNF抑制剂、IL-17抑制剂和JAK抑制剂。这篇文章提供了有价值的见解，为不断发展的景观疾病改造策略在轴性脊柱炎，突出了多方面的方法用于实现这些目标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Best Practice & Research in Clinical Rheumatology 医学-风湿病学

CiteScore

9.40

自引率

0.00%

发文量

审稿时长

27 days

期刊介绍： Evidence-based updates of best clinical practice across the spectrum of musculoskeletal conditions. Best Practice & Research: Clinical Rheumatology keeps the clinician or trainee informed of the latest developments and current recommended practice in the rapidly advancing fields of musculoskeletal conditions and science. The series provides a continuous update of current clinical practice. It is a topical serial publication that covers the spectrum of musculoskeletal conditions in a 4-year cycle. Each topic-based issue contains around 200 pages of practical, evidence-based review articles, which integrate the results from the latest original research with current clinical practice and thinking to provide a continuous update. Each issue follows a problem-orientated approach that focuses on the key questions to be addressed, clearly defining what is known and not known. The review articles seek to address the clinical issues of diagnosis, treatment and patient management. Management is described in practical terms so that it can be applied to the individual patient. The serial is aimed at the physician in both practice and training.